-
NMPA Announcement on Approval of Adding the Filing Function for the First Importation of Chemicals to the Chongqing Municipal Medical Products Administration
2021-02-07
The NMPA has approved the application of the Chongqing Municipal Medical Products Administration for adding the filing function for the first importation of chemicals, and this Announcement was hereby issued on February 2 as follows.
-
NMPA Announcement on Regulating Weian Capsules as Non-prescription Drugs
2021-02-01
According to the Provisions for the Classification Management of Prescription and Non-prescription Drugs (Interim), after the demonstration and review organized by the NMPA, the Weian Capsules are approved to be regulated as non-prescription drugs.
-
NMPA Announcement on Adopting ICH Guideline E9 (R1)
2021-01-25
To keep pace with the international technical standards for drug registration, the NMPA has decided to adopt the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Guideline E9 (R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials.
-
NMPA Announcement on Adopting ICH Guidelines S5 (R3) and S11
2021-01-25
To keep pace with the international technical standards for drug registration, the NMPA has decided to adopt two guidelines of ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use).
-
NMPA Announcement on the Application of ICH Guideline E9 (R1): Estimands and Sensitivity Analysis in Clinical Trials
2021-01-21
To keep pace with the international technical standards for drug registration, the NMPA has decided to recommend the application of ICH Guideline E9 (R1): Estimands and Sensitivity Analysis in Clinical Trials.
-
NMPA Announcement on Revising the Package Inserts of Sulfasalazine Preparations
2021-01-14
To further protect public medication safety, the NMPA decided to revise the package inserts of Sulfasalazine Preparations. The relevant issues are hereby announced as follows.
